Alphacentric Lifesci Healthcare Fund Investor Sentiment

LYFCX Fund  USD 12.94  0.11  0.84%   
Slightly above 62% of Alphacentric Lifesci's investor base is looking to short. The analysis of overall sentiment of trading Alphacentric Lifesci Healthcare mutual fund suggests that many investors are alarmed at this time. Alphacentric Lifesci's investing sentiment can be driven by a variety of factors including economic data, Alphacentric Lifesci's earnings reports, geopolitical events, and overall market trends.
  
over a year ago at news.google.com         
Morgan Stanley Maintains Airsculpt Technologies Equal ... - Nasdaq
Google News at Macroaxis
over a year ago at news.google.com         
Morgan Stanley Maintains Airsculpt Technologies Equal ... - Nasdaq
Google News at Macroaxis
over a year ago at news.google.com         
Unusual Call Option Trade in Airsculpt Technologies Worth ... - Nasdaq
Google News at Macroaxis
a day ago at statnews.com         
STAT Gilead to test once-a-year HIV prevention shot
news
2 days ago at seekingalpha.com         
Disposition of 3640 shares by Andrew Dickinson of Gilead Sciences subject to Rule 16b-3
seekingalpha News
3 days ago at gurufocus.com         
Gilead Sciences Inc Announces Promising Five-Year Results for Yescarta in Treating ...
Gurufocus Stories at Macroaxis
few days ago at finance.yahoo.com         
Kite Presents New Data Underscoring Curative Potential of Yescarta in RelapsedRefractory Large B-cel...
Yahoo News
few days ago at finance.yahoo.com         
Chronic Pseudomonas Aeruginosa Pulmonary Infections Pipeline Insight 2024 - Pipeline Drug Profiles, ...
Yahoo News
six days ago at zacks.com         
FDA Accepts Roches Columvi sBLA for Expanded Use in Lymphoma
zacks News
over a week ago at finance.yahoo.com         
Coccidioidomycosis Drugs Market to Reach US 634.3 Million by 2034, Expanding at a CAGR of 4.9 percen...
Yahoo News
over a week ago at gurufocus.com         
Gilead Sciences Partners with Tubulis to Develop Antibody-Drug Conjugates
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Is Gilead a Buy as Wall Street Analysts Look Optimistic?
Yahoo News
over a week ago at investing.com         
Gilead Sciences CFO sells 23 million in stock
Investing News at Macroaxis
a day ago at finance.yahoo.com         
Tampa General Hospital Recognized as Top Hospital for Maternity Care by U.S. News World Report
Yahoo News
3 days ago at finance.yahoo.com         
Vertex Has 5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Yahoo News
few days ago at finance.yahoo.com         
Vertex Presents Positive Long-Term Data On CASGEVY at the American Society of Hematology Annual Meet...
Yahoo News
few days ago at finance.yahoo.com         
GOOGLs PaliGemma 2 Expands AI Portfolio Buy, Sell or Hold the Stock?
Yahoo News
few days ago at finance.yahoo.com         
Is AI the Future for Salesforce Insights from Recent Earnings
Yahoo News
six days ago at thelincolnianonline.com         
Vertex Pharmaceuticals Incorporated Stock Position Lowered by SageView Advisory Group LLC
news
six days ago at finance.yahoo.com         
Alphabet Inc. Hosts Record-Breaking Gen AI Intensive Course with Over 140,000 Registrants
Yahoo News
over a week ago at thelincolnianonline.com         
Reynders McVeigh Capital Management LLC Boosts Stake in Vertex Pharmaceuticals Incorporated
news
over a week ago at seekingalpha.com         
CMS rolls out new payment model for Vertex, bluebird gene therapies
seekingalpha News
over a week ago at zdnet.com         
Googles AI video generator rolls out in private preview. Heres who can access
news
over a week ago at investing.com         
Viracta Therapeutics faces Nasdaq delisting over non-compliance
Investing News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Lisa Rojkjaer of 4127 shares of Viracta Therapeutics subject to Rule 16b-3
Macroaxis News
over three weeks ago at news.google.com         
Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
Sunesis Advisors LLC Sells 277 Shares of iShares SP Mid-Cap 400 Value ETF
news
over two months ago at thelincolnianonline.com         
Viracta Therapeutics, Inc. Short Interest Update
news
over three months ago at finance.yahoo.com         
Heres Why Sunesis Is a Great Buy the Bottom Stock Now
Yahoo News
over three months ago at news.google.com         
Viracta Therapeutics PT Lowered to 4.00 - Defense World
Google News at Macroaxis
over three months ago at benzinga.com         
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?
benzinga news
over three months ago at seekingalpha.com         
Viracta Therapeutics GAAP EPS of -0.25 beats by 0.11
seekingalpha News
over three months ago at finance.yahoo.com         
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, an...
Yahoo News
a day ago at benzinga.com         
1000 Invested In United Therapeutics 20 Years Ago Would Be Worth This Much Today
benzinga news
3 days ago at finance.yahoo.com         
Are You a Growth Investor This 1 Stock Could Be the Perfect Pick
Yahoo News
few days ago at thelincolnianonline.com         
Paul A. Mahon Sells 7,700 Shares of United Therapeutics Co. Stock
news
few days ago at zacks.com         
Are You a Value Investor This 1 Stock Could Be the Perfect Pick
zacks News
over a week ago at kalkinemedia.com         
Pulmonary Arterial Hypertension Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by De...
news
over a week ago at finance.yahoo.com         
Disposition of 100 shares by Michael Benkowitz of United Therapeutics at 374.48 subject to Rule 16b-...
Yahoo News
over a week ago at finance.yahoo.com         
Tempus AI, Inc Stock Soars 75 percent Post-Earnings, but Stifel Downgrades to Hold Due to Overvaluat...
Yahoo News
over a week ago at thelincolnianonline.com         
21,448 Shares in United Therapeutics Co. Bought by Tri Ri Asset Management Corp
news
over two weeks ago at investing.com         
Earnings call 3D Systems faces headwinds in Q3 amid global uncertainty
Investing News at Macroaxis
over two weeks ago at zacks.com         
Disposition of 300 shares by Michael Benkowitz of United Therapeutics at 371.152 subject to Rule 16b...
zacks News
a minute ago at finance.yahoo.com         
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Disease...
Yahoo News
3 days ago at thelincolnianonline.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
news
few days ago at investing.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Investing News at Macroaxis
few days ago at zacks.com         
Why Is Sarepta Therapeutics Up 4.9 percent Since Last Earnings Report?
zacks News
six days ago at www.macroaxis.com         
Disposition of 1636 shares by Boor Kathryn Jean of Sarepta Therapeutics at 125.55 subject to Rule 16...
Macroaxis News
over a week ago at investing.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Investing News at Macroaxis
over a week ago at investing.com         
Sarepta Therapeutics SWOT analysis gene therapy leaders stock poised for growth
Investing News at Macroaxis
over a week ago at thelincolnianonline.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
news
over a week ago at thelincolnianonline.com         
Fred Alger Management LLC Sells 31,373 Shares of Sarepta Therapeutics, Inc.
news
over a week ago at businesswire.com         
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
a day ago at investing.com         
Disc Medicines SWOT analysis stock potential amid mixed trial results
Investing News at Macroaxis
3 days ago at gurufocus.com         
Regeneron Pharmaceuticals Inc Showcases Promising Results for Odronextamab in Lymphoma Trials
Gurufocus Stories at Macroaxis
few days ago at gurufocus.com         
Regeneron Pharmaceuticals Inc Announces Promising Phase 3 Trial Results for Poze-Cemdi ...
Gurufocus Stories at Macroaxis
few days ago at thefly.com         
Regeneron announces Phase 3 data of exploratory cohort from ACCESS-1 trial REGN
news
few days ago at thelincolnianonline.com         
Regeneron Pharmaceuticals, Inc. Stake Lessened by Zurich Insurance Group Ltd FI
news
six days ago at finance.yahoo.com         
Sapience Therapeutics Strengthens Board of Directors and Management Team with Esteemed Business Deve...
Yahoo News
over a week ago at gurufocus.com         
Glancy Prongay Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation ...
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Viral Sensitizers Market Set to Reach USD 7,950.80 Million By 2034 with a Notable CAGR of 14.6 perce...
Yahoo News
over a week ago at gurufocus.com         
Regeneron Pharmaceuticals Inc Faces Legal Scrutiny Over Alleged Medicare Fraud
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
This Stock Just Dropped by 12 percent in 1 Day Should You Buy the Dip?
Yahoo News
a day ago at zacks.com         
QURE Soars on FDA Alignment for Speedy Approval of Huntingtons Drug
zacks News
3 days ago at news.google.com         
Disposition of 1796 shares by Christian Klemt of Uniqure NV at 7.55 subject to Rule 16b-3
Google News at Macroaxis
few days ago at simplywall.st         
Is There An Opportunity With uniQure N.V.s percent Undervaluation?
Simply Wall St News at Macroaxis
over two weeks ago at globenewswire.com         
uniQure Announces Dosing of First Patient in GenTLE Phase IIIa Clinical Trial of AMT-260 for the Tre...
Macroaxis News: globenewswire.com
over two weeks ago at thelincolnianonline.com         
uniQure Announces Dosing of First Patient in GenTLE Phase IIIa Clinical Trial of AMT-260 for Refract...
news
over a month ago at thelincolnianonline.com         
Royal Bank of Canada Has Lowered Expectations for uniQure Stock Price
news
over a month ago at finance.yahoo.com         
What Does The Future Hold For uniQure N.V. These Analysts Have Been Cutting Their Estimates
Yahoo News
over a month ago at finance.yahoo.com         
UniQure Q3 Earnings Snapshot
Yahoo News
over a month ago at zacks.com         
Select Medical Q3 Earnings and Revenues Surpass Estimates
zacks News
over a month ago at thelincolnianonline.com         
uniQure Raised to Sell at StockNews.com
news
over a year ago at news.google.com         
Nivolumab Plus Relatlimab Induces Durable Responses in ... - OncLive
Google News at Macroaxis
a minute ago at finance.yahoo.com         
Merck and GTRI to develop gene therapy for Parkinsons disease
Yahoo News
2 days ago at fxstreet.com         
Dow Jones Industrial Average flattens on cautious Tuesday
Fxstreet News at Macroaxis
3 days ago at finance.yahoo.com         
Antidepressant Drugs Market is expected to reach a revenue of USD 26.9 Bn by 2033, at 3.3 percent CA...
Yahoo News
few days ago at businesswire.com         
Mercks Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response...
businesswire News
few days ago at thelincolnianonline.com         
Merck Co., Inc. Stake Lessened by Zurich Insurance Group Ltd FI
news
few days ago at zacks.com         
Pharma Stock Roundup LLYs Zepbound Success, FDA Updates for MRK, JNJ
zacks News
few days ago at insidermonkey.com         
Why Merck Co. Is Among the Best Affordable Stocks to Buy Right Now
insidermonkey News
six days ago at investing.com         
Ginkgo Bioworks CFO Mark Dmytruk sells 7,146 in stock
Investing News at Macroaxis
over a week ago at investing.com         
HSBC bullish on Merck stock, cites credible strategy and oncology expertise
Investing News at Macroaxis
over a week ago at gurufocus.com         
Merck Receives FDA Breakthrough Therapy Designation for Sac-TMT
Gurufocus Stories at Macroaxis
a minute ago at simplywall.st         
Jazz Pharmaceuticals investors are sitting on a loss of 20 percent if they invested a year ago
Simply Wall St News at Macroaxis
3 days ago at thelincolnianonline.com         
Jazz Pharmaceuticals plc Shares Sold by First National Bank of Omaha
news
few days ago at simplywall.st         
Based On Its ROE, Is Jazz Pharmaceuticals plc A High Quality Stock?
Simply Wall St News at Macroaxis
few days ago at finance.yahoo.com         
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex Benefits and Broad-Sp...
Yahoo News
six days ago at gurufocus.com         
Disposition of tradable shares by Renee Gala of Jazz Pharmaceuticals at 123.45 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Jazz Pharmaceuticals CEO Bruce Cozadd sells 242,340 in shares
Investing News at Macroaxis
over a week ago at aol.com         
Disposition of tradable shares by Patricia Carr of Jazz Pharmaceuticals at 122.49 subject to Rule 16...
news
over a week ago at finance.yahoo.com         
Why Jazz Pharmaceuticals Is One of the Most Undervalued Pot Stocks to Buy?
Yahoo News
over two weeks ago at forbes.com         
EFG London Jazz Festivals Top Acts And Where To See Them Next
Usa forbes News
over two weeks ago at finance.yahoo.com         
Jazz Aviation LP kicks off 2024 holiday season with first Searching for Santa flight
Yahoo News
a day ago at zacks.com         
Acquisition by Clancy Paul J of 403 shares of Incyte at 56.97 subject to Rule 16b-3
zacks News
3 days ago at seekingalpha.com         
Incyte reports positive Phase 3 data for Zynyz for lung cancer
seekingalpha News
3 days ago at finance.yahoo.com         
Disposition of 1510 shares by Flannelly Barry P of Incyte at 72.11 subject to Rule 16b-3
Yahoo News
few days ago at businesswire.com         
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Pla...
businesswire News
few days ago at finance.yahoo.com         
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Pla...
Yahoo News
few days ago at businesswire.com         
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
six days ago at investors.com         
Stocks With Rising Relative Price Strength Incyte
Investors Business Daily at Macroaxis
over a week ago at thelincolnianonline.com         
PDT Partners LLC Has 313,000 Stake in Incyte Co.
news
over a week ago at finance.yahoo.com         
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT in Combination with ELUNA...
Yahoo News
over a week ago at finance.yahoo.com         
Insider Trading
Yahoo News
six days ago at news.google.com         
Immunovants SWOT analysis stock undervalued amid promising Graves disease treatment - Investing.com
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 4747 shares by Barnett Eva Renee of Immunovant at 28.06 subject to Rule 16b-3
Macroaxis News
over two weeks ago at news.google.com         
Insider Selling Immunovant, Inc. CEO Sells 16,692 Shares of Stock - MarketBeat
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 16692 shares by Salzmann Peter of Immunovant at 25.45 subject to Rule 16b-3
Macroaxis News
over three weeks ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires New Stake in Kineta Inc
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires New Stake in Rekor Systems Inc
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
FMR LLCs Strategic Acquisition of Immunovant Inc Shares
Gurufocus Stories at Macroaxis
over a month ago at seekingalpha.com         
Immunovant GAAP EPS of -0.74
seekingalpha News
over a month ago at investing.com         
Immunovant CTO Jay Stout sells 80,912 in stock
Investing News at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 150000 shares by Geffner Michael of Immunovant at 18.06 subject to Rule 16b-3
Macroaxis News
over a year ago at www.macroaxis.com         
Disposition of 110447 shares by Thomas Watkins of Horizon Pharma subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Institutional owners may consider drastic measures as Vir Biotechnology, Inc.s recent US85m drop add...
Google News at Macroaxis
over a year ago at businesswire.com         
Horizon Therapeutics plc Rule 2.12 Announcement
businesswire News
over a year ago at benzinga.com         
Heres How Much 1000 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth Today
benzinga news
over a year ago at news.google.com         
U.S. FTC allows Amgen to move forward with 27.8 bln Horizon deal - CNBC - Marketscreener.com
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Toronto Dominion Bank Buys 185,145 Shares of Horizon Therapeutics Public Limited
news
over a year ago at finance.yahoo.com         
Horizon Up as FTC Pauses Acquisition by Amgen Lawsuit
Yahoo News
over a year ago at finance.yahoo.com         
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocac...
Yahoo News
over a year ago at marketwatch.com         
George Soros has a big stake in this stock but its posted a roughly 9 percent loss this year. Are th...
marketwatch News
over a year ago at thelincolnianonline.com         
Horizon Therapeutics Public Issues Earnings Results
news
over a week ago at thelincolnianonline.com         
Galapagos NV Short Interest Up 5.6 percent in November
news
over three weeks ago at thelincolnianonline.com         
Galapagos NV Short Interest Down 6.6 percent in October
news
over three weeks ago at gurufocus.com         
FMR LLC Adjusts Stake in Galapagos NV
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Galapagos Third Quarter 2024 Earnings 0.74 loss per share - Yahoo Finance
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
Galapagos Shares Gap Down Time to Sell?
news
over two months ago at thelincolnianonline.com         
Galapagos NV Receives 31.00 Consensus Target Price from Analysts
news
over three months ago at benzinga.com         
Major Investor Says Galapagos Is Undervalued, Plans To Push On Companys Performance And Strategic Op...
benzinga news
over three months ago at seekingalpha.com         
Galapagos stock gains after FDA nod for trial
seekingalpha News
over three months ago at insidermonkey.com         
Galapagos NV Q2 2024 Earnings Call Transcript
insidermonkey News
over three months ago at seekingalpha.com         
Galapagos stock downgraded at Raymond James
seekingalpha News
a day ago at gurufocus.com         
ACADIA Pharmaceuticals Sells Priority Review Voucher for 150 Million
Gurufocus Stories at Macroaxis
3 days ago at gurufocus.com         
Insider Trading
Gurufocus Stories at Macroaxis
six days ago at gurufocus.com         
ACADIA HEALTHCARE SHAREHOLDER ALERT CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF ...
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Why Acadia Pharmaceuticals is a Top Momentum Stock for the Long-Term
Yahoo News
over a week ago at gurufocus.com         
ACADIA HEALTHCARE COMPANY, INC. DEADLINE ALERT Bernstein Liebhard LLP Reminds ...
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
ACADIA Pharmaceuticals SWOT analysis stock outlook mixed as DAYBUE launch faces hurdles
Investing News at Macroaxis
over two weeks ago at businesswire.com         
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
businesswire News
over two weeks ago at prnewswire.com         
ACADIA HEALTHCARE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL KAHN SWICK FOTI, LLC REMIND...
prnewswire News
over two weeks ago at investing.com         
Acadia Pharmaceuticals COO sells 173,630 in stock
Investing News at Macroaxis
over three weeks ago at gurufocus.com         
Disposition of 10259 shares by Mark Schneyer of ACADIA Pharmaceuticals at 16.81 subject to Rule 16b-...
Gurufocus Stories at Macroaxis
2 days ago at finance.yahoo.com         
Lilly Announces New 15B Stock Buyback Plan, Ups Dividend by 15
Yahoo News
3 days ago at finance.yahoo.com         
Exelixis is an Incredible Growth Stock 3 Reasons Why
Yahoo News
few days ago at thelincolnianonline.com         
Two Sigma Advisers LP Acquires 98,000 Shares of Exelixis, Inc.
news
six days ago at thelincolnianonline.com         
NFJ Investment Group LLC Makes New Investment in Exelixis, Inc.
news
over a week ago at finance.yahoo.com         
Why Is Editas Down 36.5 percent Since Last Earnings Report?
Yahoo News
over a week ago at talkmarkets.com         
Ulta Beauty To Come Up With Q3 Earnings Is A Beat Likely For ULTA?
news
over a week ago at simplywall.st         
Is Exelixis, Inc.s Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Simply Wall St News at Macroaxis
over a week ago at zacks.com         
Disposition of 15000 shares by Hessekiel Jeffrey of Exelixis subject to Rule 16b-3
zacks News
over two weeks ago at investing.com         
Exelixis EVP Haley Patrick J. sells 352,700 in stock
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Disposition of 129314 shares by Hessekiel Jeffrey of Exelixis at 18.8 subject to Rule 16b-3
Yahoo News
over a year ago at gurufocus.com         
Top 5 4th Quarter Trades of BP PLC
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended D...
Google News at Macroaxis
over two weeks ago at news.google.com         
Collegium Pharmaceutical, Inc. Receives Average Recommendation of Moderate Buy from Brokerages - Mar...
Google News at Macroaxis
over three weeks ago at thelincolnianonline.com         
Empowered Funds LLC Acquires New Position in Collegium Pharmaceutical, Inc.
news
over three weeks ago at gurufocus.com         
Rubric Capital Management LP Adjusts Stake in Collegium Pharmaceutical Inc
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
Is Collegium Pharmaceutical a Great Value Stock Right Now?
Yahoo News
over three weeks ago at gurufocus.com         
Collegium Pharmaceutical Inc Stock Price Down 3.67 percent on Nov 12
Gurufocus Stories at Macroaxis
over a month ago at zacks.com         
Is the Options Market Predicting a Spike in Collegium Pharmaceutical Stock?
zacks News
over a month ago at finance.yahoo.com         
Collegium Pharmaceutical Inc Q3 2024 Earnings Call Highlights Record Revenue Growth and ...
Yahoo News
over a month ago at finance.yahoo.com         
Collegium Pharmaceutical Q3 Earnings Snapshot
Yahoo News
over a month ago at finance.yahoo.com         
Heres What Key Metrics Tell Us About Collegium Pharmaceutical Q3 Earnings
Yahoo News
a day ago at news.google.com         
Cogent Biosciences Stock Rating Lowered by Needham Company LLC - MarketBeat
Google News at Macroaxis
few days ago at gurufocus.com         
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating ...
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Acquisition by Sachs Jessica of 126500 shares of Cogent Biosciences at 10.17 subject to Rule 16b-3
news
over three weeks ago at news.google.com         
Cogent Biosciences Shares Down 7 percent - Should You Sell - MarketBeat
Google News at Macroaxis
over three weeks ago at gurufocus.com         
Kynam Capital Management, LP Increases Stake in Vera Therapeutics Inc
Gurufocus Stories at Macroaxis
over three weeks ago at globenewswire.com         
Cogent Biosciences Reports Recent Business Highlights andThird Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
over a month ago at gurufocus.com         
FMR LLC Acquires Additional Shares in Cogent Biosciences Inc
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Harwin Peter Evan of 60000 shares of Cogent Biosciences at 8.45 subject to Rule 16b-3
Macroaxis News
over two months ago at thelincolnianonline.com         
Analysts Set Cogent Biosciences, Inc. PT at 15.00
news
over two months ago at news.google.com         
Point72 Asset Management L.P. Increases Position in Cogent Biosciences, Inc. - MarketBeat
Google News at Macroaxis
a day ago at news.google.com         
Jacobs Levy Equity Management Inc. Has 262,000 Stock Holdings in Coherus BioSciences, Inc. - MarketB...
Google News at Macroaxis
over a week ago at investing.com         
Coherus Biosciences stock rating maintained at Buy, price target cut by 41.7
Investing News at Macroaxis
over a week ago at seekingalpha.com         
Coherus BioSciences to divest UDENYCA franchise for up to 558.4M
seekingalpha News
over a week ago at benzinga.com         
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
benzinga news
over a week ago at zacks.com         
Heres Why You Should Add Dr. Reddys Stock to Your Portfolio
zacks News
over two weeks ago at news.google.com         
Coherus BioSciences Inc Q2 2024 Earnings Call Highlights Strong Revenue Growth and Strategic Advance...
Google News at Macroaxis
over a month ago at insidermonkey.com         
Coherus BioSciences, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a month ago at thelincolnianonline.com         
HC Wainwright Reiterates Buy Rating for Coherus BioSciences
news
over a month ago at seekingalpha.com         
Coherus BioSciences Non-GAAP EPS of -0.01 beats by 0.10, revenue of 70.77M beats by 13.96M
seekingalpha News
over a month ago at seekingalpha.com         
Coherus BioSciences Q3 2024 Earnings Preview
seekingalpha News
few days ago at news.google.com         
Zimmer Partners LP Invests 1.95 Million in Blueprint Medicines Co. - MarketBeat
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Why Is Cogent Biosciences, Inc. Among the Best Small-Cap Biotech Stocks With Massive Potential Accor...
Yahoo News
over a week ago at thelincolnianonline.com         
Edgestream Partners L.P. Has 5.19 Million Holdings in Blueprint Medicines Co.
news
over a week ago at thelincolnianonline.com         
2,998 Shares in Blueprint Medicines Co. Bought by Blueshift Asset Management LLC
news
over two weeks ago at finance.yahoo.com         
AffyImmune Appoints Deyaa Adib, MD as Chief Medical Officer
Yahoo News
over two weeks ago at news.google.com         
Disposition of 9824 shares by Coats Lonnel of Blueprint Medicines at 94.87 subject to Rule 16b-3
Google News at Macroaxis
over three weeks ago at news.google.com         
Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. - MarketBeat
Google News at Macroaxis
over three weeks ago at investing.com         
Blueprint Medicines stock underpriced with 2bn peak sales in sight, per JPMorgan
Investing News at Macroaxis
over a month ago at thelincolnianonline.com         
97,861 Shares in Blueprint Medicines Co. Bought by MG Plc
news
over a month ago at thelincolnianonline.com         
Blueprint Medicines Co. Shares Bought by Emerald Advisers LLC
news
a day ago at zacks.com         
BioMarin Pharmaceutical is a Top-Ranked Momentum Stock Should You Buy?
zacks News
3 days ago at thelincolnianonline.com         
United Services Automobile Association Trims Stake in BioMarin Pharmaceutical Inc.
news
six days ago at kalkinemedia.com         
Long BMRN BioMarin Q3 Earnings Deliver 28 percent Revenue Growth, Raised Guidance, and Bullish Rever...
news
six days ago at finance.yahoo.com         
Why Is Beam Therapeutics Down 2.3 percent Since Last Earnings Report?
Yahoo News
over a week ago at thelincolnianonline.com         
Fred Alger Management LLC Sells 2,943 Shares of BioMarin Pharmaceutical Inc.
news
over a week ago at thelincolnianonline.com         
Acquisition by Countouriotis Athena of 4720 shares of Biomarin Pharmaceutical subject to Rule 16b-3
news
over a week ago at zacks.com         
Why Is BioMarin Down 1.9 percent Since Last Earnings Report?
zacks News
over two weeks ago at finance.yahoo.com         
Why Is BioMarin Pharmaceutical Inc. Among the Worst Performing Healthcare Stocks in 2024?
Yahoo News
over two weeks ago at zacks.com         
Heres Why BioMarin Pharmaceutical is a Strong Value Stock
zacks News
over two weeks ago at insidermonkey.com         
Why Is BioMarin Pharmaceutical Inc. Among the Worst Performing Biotech Stocks in 2024?
insidermonkey News
few days ago at businesswire.com         
bluebird bio Presents Positive Long-Term Data On LYFGENIA Gene Therapy for Sickle Cell Disease at 66...
businesswire News
few days ago at finance.yahoo.com         
bluebird bio Presents Positive Long-Term Data On LYFGENIA Gene Therapy for Sickle Cell Disease at 66...
Yahoo News
few days ago at businesswire.com         
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for -Th...
businesswire News
few days ago at businesswire.com         
ISS Recommends Dye Durham Shareholders Vote the BLUE Proxy Card FOR Three of Engine Capitals Directo...
businesswire News
over a week ago at finance.yahoo.com         
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation Cell and Gene The...
Yahoo News
over a week ago at benzinga.com         
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
benzinga news
over a week ago at finance.yahoo.com         
Isle Blue Unveils VIP Villa Collection Featuring the Worlds Most Exclusive Private Islands and Estat...
Yahoo News
over a week ago at thelincolnianonline.com         
bluebird bio Research Coverage Started at StockNews.com
news
over a week ago at prnewswire.com         
BLUE LOCK CEMENTS ITSELF AS AN INTERNATIONAL HIT AS EPISODE NAGI EARNS 23.3 MILLION AT THE GLOBAL BO...
prnewswire News
over two weeks ago at investing.com         
Bluebird Bios SWOT analysis gene therapy firm faces cash crunch amid launch
Investing News at Macroaxis
a minute ago at kalkinemedia.com         
Japan gives priority review status to Alzheimers drug developed by Eisai, Biogen
news
2 days ago at finance.yahoo.com         
eBay downgraded, GM upgraded Wall Streets top analyst calls
Yahoo News
3 days ago at investing.com         
Biogens head of development sells shares worth 17,293
Investing News at Macroaxis
few days ago at thelincolnianonline.com         
Disposition of 634 shares by Ginger Gregory of Biogen at 240.98 subject to Rule 16b-3
news
few days ago at finance.yahoo.com         
Disposition of 351 shares by Robin Kramer of Biogen subject to Rule 16b-3
Yahoo News
six days ago at finance.yahoo.com         
Leqembi approved in Mexico
Yahoo News
six days ago at seekingalpha.com         
Laggard stocks with expanding FCF margins and attractive FCF yields Goldman
seekingalpha News
over a week ago at finance.yahoo.com         
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma...
Yahoo News
over a week ago at finance.yahoo.com         
Psoriasis Drug Market is Expected to Reach US27.57 Billion with 6.9 percent CAGR by 2034 Fact.MR Rep...
Yahoo News
over a week ago at medcitynews.com         
Challenges and Opportunities for Digital Innovation in Clinical Trials
news
over a year ago at finance.yahoo.com         
Orphan Drug Market Size Share to Surpass 3199.3 Billion by 2028 Vantage Market Research
Yahoo News
a day ago at news.google.com         
Point72 Asset Management L.P. Purchases New Position in Allakos Inc. - MarketBeat
Google News at Macroaxis
six days ago at www.macroaxis.com         
Disposition of 32466 shares by Robert Alexander of Allakos at 1.1 subject to Rule 16b-3
Macroaxis News
over three weeks ago at news.google.com         
Allakos Inc. finalizes early lease termination, incurring 2.5 million in costs - Investing.com
Google News at Macroaxis
over a month ago at zacks.com         
All You Need to Know About Allakos Rating Upgrade to Buy
zacks News
over a month ago at simplywall.st         
Allakos Insiders Miss 24 percent Gain After Offloading Stock
Simply Wall St News at Macroaxis
over two months ago at thelincolnianonline.com         
JMP Securities Reaffirms Market Outperform Rating for Allakos
news
over two months ago at news.google.com         
Allakos stock plunges to 52-week low of 0.56 amid market challenges - Investing.com
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 13665 shares by Radford Harlan Baird of Allakos at 0.65 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Vanguard Group Inc. Raises Stock Holdings in Allakos Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Allakos stock plunges to 52-week low of 0.67 amid steep annual decline - Investing.com
Google News at Macroaxis
over a year ago at news.google.com         
Current and Future Analysis of Rho Kinases Inhibitor Market With New Business Strategies and Forecas...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Alphacentric Lifesci that are available to investors today. That information is available publicly through Alphacentric media outlets and privately through word of mouth or via Alphacentric internal channels. However, regardless of the origin, that massive amount of Alphacentric data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alphacentric Lifesci news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alphacentric Lifesci relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alphacentric Lifesci's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alphacentric Lifesci alpha.

Other Information on Investing in Alphacentric Mutual Fund

Alphacentric Lifesci financial ratios help investors to determine whether Alphacentric Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alphacentric with respect to the benefits of owning Alphacentric Lifesci security.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings